These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11192745)

  • 41. [Standard pharmacological therapy associated with percutaneous coronary interventions in patients with stable angina].
    Karcz M; Ruzyłło W
    Kardiol Pol; 2004 Nov; 61(11):480-2. PubMed ID: 15883598
    [No Abstract]   [Full Text] [Related]  

  • 42. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
    Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G
    Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML; Merlini PA
    Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract]   [Full Text] [Related]  

  • 45. Optimizing outcomes in ST-segment elevation myocardial infarction.
    Herrmann HC
    J Am Coll Cardiol; 2003 Oct; 42(8):1357-9. PubMed ID: 14563574
    [No Abstract]   [Full Text] [Related]  

  • 46. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycoprotein IIb/IIIa inhibitor (tirofiban) in acute ST-segment elevation myocardial infarction.
    Fang CC; Jao YT; Chen Y; Yu CL; Wang SP
    Angiology; 2009; 60(2):192-200. PubMed ID: 18445614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
    Allie DE; Hebert CJ; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Vivekananthan K; Allie SE; Mitran EV; Chaisson G; Stagg SJ; Allie AA; McElderry MW; Barker EA; Walker CM
    J Invasive Cardiol; 2005 Aug; 17(8):427-32. PubMed ID: 16079449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial.
    Lee DP; Herity NA; Hiatt BL; Fearon WF; Rezaee M; Carter AJ; Huston M; Schreiber D; DiBattiste PM; Yeung AC;
    Circulation; 2003 Mar; 107(11):1497-501. PubMed ID: 12654606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GUSTO IV: expanding therapeutic options in acute coronary syndromes.
    Lincoff AM
    Am Heart J; 2000 Dec; 140(6 Suppl):S103-14. PubMed ID: 11100004
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban.
    Chung TL; Pumplin DW; Holton LH; Taylor JA; Rodriguez ED; Silverman RP
    Plast Reconstr Surg; 2007 Oct; 120(5):1281-1288. PubMed ID: 17898601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glycoprotein IIb/IIIa inhibition in percutaneous coronary interventions.
    Sharma S; Nyitray W; Bhambi B
    JAMA; 2003 Sep; 290(11):1451; author reply 1451. PubMed ID: 13129974
    [No Abstract]   [Full Text] [Related]  

  • 53. Management of acute coronary syndromes.
    Schulman SP; Fessler HE
    Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971
    [No Abstract]   [Full Text] [Related]  

  • 54. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome.
    Song Y
    J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):142-4. PubMed ID: 17497280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
    Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
    Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris.
    Soffer D; Moussa I; Karatepe M; Harjai KJ; Boura J; Dixon SR; Grines CL; O'Neill WW; Roubin GS; Moses JW
    Am J Cardiol; 2003 Apr; 91(7):872-5. PubMed ID: 12667576
    [No Abstract]   [Full Text] [Related]  

  • 59. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 60. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.